Qiagen N.V. (NYSE:QGEN) Q1 2024 Earnings Conference Call April 30, 2024 9:00 AM ET Company Participants John Gilardi - VP, Corporate Communications & IR Thierry Bernard - Chief Executive Officer Roland Sackers - Chief Financial Officer Conference Call Participants Matthew Sykes - Goldman Sachs Aisyah Noor - Morgan Stanley Michael Ryskin - Bank of America Hugo Solvet - BNP Paribas Patrick Donnelly - Citi Jack Meehan - Nephron Research Catherine Schulte - Baird Falko Friedrichs - Deutsche Bank Daniel Leonard ...

QIAGEN N.V.’s (QGEN) first-quarter 2024 adjusted earnings per share (EPS) were 46 cents and 47 cents at constant exchange rate (CER), down 9.8% year over year. However, the figure topped the Zacks Consensus Estimate by 4.6%.The adjustment excludes the impact of certain non-recurring items like business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others.The GAAP EPS for the quarter was 36 cents, down 2.7% ...

For the quarter ended March 2024, Qiagen (QGEN) reported revenue of $458.8 million, down 5.5% over the same period last year. EPS came in at $0.46, compared to $0.53 in the year-ago quarter.The reported revenue represents a surprise of +0.73% over the Zacks Consensus Estimate of $455.5 million. With the consensus EPS estimate being $0.44, the EPS surprise was +4.55%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expecta ...

Qiagen (QGEN) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.55%. A quarter ago, it was expected that this diagnostic products maker would post earnings of $0.56 per share when it actually produced earnings of $0.55, delivering a surprise of -1.79%.Over the last four quarters, the ...

Wall Street analysts forecast that Qiagen (QGEN) will report quarterly earnings of $0.44 per share in its upcoming release, pointing to a year-over-year decline of 17%. It is anticipated that revenues will amount to $454.97 million, exhibiting a decline of 6.3% compared to the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this time ...

Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.  Three options for joining the conference call Register for call back connection - Click here: C ...

Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.  Three options for joining the conference call Register for call back connection - Click here: ...

QIAGEN N.V. (QGEN) recently announced a sequence of new products to augment cancer research further and to enable urine collection and stabilization as a new approach for liquid biopsy. The three new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.The new products are likely to be featured at the annual meeting of the American Association for Cancer Research (AACR) in San Diego, California, from Apr 5-10.Product DetailsThe first produc ...

Venlo, the Netherlands, April 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a series of new products to further enhance cancer research as well as to enable urine collection and stabilization as a new approach for liquid biopsy. These three new products, along with the IVD version of QIAGEN's digital PCR platform QIAcuity set for launch in mid-2024, are to be featured at the annual meeting of the American Association for Cancer Research (AACR) in San D ...

Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements. A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers. This collaboration f ...